# Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS

> **NCT02446886** · PHASE4 · TERMINATED · sponsor: **Weill Medical College of Cornell University** · enrollment: 15 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)

## Key facts

- **NCT ID:** NCT02446886
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06
- **Primary completion:** 2020-03
- **Final completion:** 2020-06
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Slow enrollment
- **Last updated:** 2021-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02446886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02446886, "Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT02446886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*